CX3CR1 antagonist 18a (AZD8797) is the first potent selective and orally available CX3CR1 allosteric antagonist. AZD8797 is able to non-competitively displace and block CX3CL1 from binding CX3CR1 through an allosteric binding mechanism of action. AZD8797 effects G-protein signaling and β-arrestin recruitment in a biased way. Starting treatment with AZD8797 either before or after onset of disease reduced the clinical symptoms and pathological signs of experimental autoimmune encephalomyelitis (EAE) (the model of multiple sclerosis) in a concentration-dependent manner. CX3CR1 (Fractalkine) signaling probably contributes to the growth and spread of tumors and the pain that often affects cancer patients. Kancera will now evaluate how efficiently the Fractalkine inhibitor AZD8797 may stop tumor growth and relieve severe pain.